Noradrenalin Pfizer (Noradrenaline Tartrate)

Noradrenaline acts as a direct agonist at alpha‑adrenergic receptors on vascular smooth muscle, causing strong vasoconstriction that increases systemic vascular resistance and arterial pressure. It also stimulates beta‑1 receptors modestly, which can enhance heart contractility and cardiac output.

The dose of Noradrenalin Pfizer is individualized and set by the prescribing clinician. It is typically started at a low infusion rate and titrated based on the patient’s blood pressure response, with continuous hemodynamic monitoring.

Safety data for noradrenaline in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Noradrenalin is the first‑line vasopressor for most forms of shock because of its potent alpha‑adrenergic activity and relatively predictable effect on blood pressure. Compared with dopamine, it has less tachyarrhythmic risk, and unlike epinephrine, it causes less increase in heart rate while still providing strong vasoconstriction.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen. It should be kept in its original packaging until use and handled with aseptic technique to maintain sterility.

Noradrenalin Pfizer is given by intravenous infusion, often through a central line. A controlled infusion pump is used to titrate the dose while continuously monitoring blood pressure and heart rate. In some emergency situations, a rapid bolus may be administered under strict supervision.

The most serious adverse events include severe hypertension, myocardial ischemia, life‑threatening arrhythmias, and tissue necrosis if the drug extravasates from the vein. Immediate recognition and management of these events are essential during therapy.

Contraindications include patients with known hypersensitivity to noradrenaline or its excipients, those with pheochromocytoma, and individuals in whom uncontrolled hypertension would pose a high risk. Use in such patients should be avoided or undertaken only with specialist supervision.